Palazestrant in the clinic.

Our lead investigational drug, palazestrant (OP-1250), is a novel oral compound developed to completely antagonize the estrogen receptor (ER) and block the ER-mediated cancer cell growth and proliferation signal.

Our pipeline

Target Patient Population

Discovery

Nonclinical

Phase I

Phase II

Phase III

Clinical
Collaboration

Palazestrant (OP-1250) - ER+/HER2- Metastatic Breast Cancer

1st line combo with CDK 4/6i ribociclib

2/3 line monotherapy

Combo therapy with CDK4/6i ribociclib

Combo therapy with CDK4/6i palbociclib

Combo therapy with PI3Ki alpelisib with PIK3CA mutated

Combo therapy with mTOR inhibitor everolimus

OP-3136 KAT6 Inhibitor - Oncology

ER+/HER2+ metastatic breast cancer/castrate-resistant prostate/lung cancer